|
Kidney Failure, Chronic
|
0.400 |
Biomarker
|
disease |
BEFREE |
Erythropoiesis-stimulating agents (eg, epoetin alfa) are the primary treatment for anemia in patients with end-stage renal disease.
|
30412269 |
2019 |
|
Kidney Failure, Chronic
|
0.400 |
Biomarker
|
disease |
BEFREE |
Parental iron is used to optimize hemoglobin and enhance erythropoiesis in end-stage renal disease along with erythropoietin-stimulating agents.
|
31485910 |
2019 |
|
Kidney Failure, Chronic
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Creatinine, uric acid, and EPO levels had correlations with the performance of stored RBCs in ESRD plasma.
|
30888086 |
2019 |
|
Kidney Failure, Chronic
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here, we determined whether EPO levels correlate with the incidence of different dementia subtypes, including Alzheimer's disease (AD), vascular dementia (VaD), and unspecified dementia (UnD), and whether such associations vary with annual cumulatively defined daily doses (DDDs) of EPO for ESRD patients receiving HD.
|
31484803 |
2019 |
|
Kidney Failure, Chronic
|
0.400 |
Biomarker
|
disease |
BEFREE |
Erythropoietin-stimulating agent hyporesponsiveness (ESAH) is associated with increased cardiovascular mortality in patients with end-stage renal disease (ESRD) on hemodialysis.
|
29619552 |
2018 |
|
Kidney Failure, Chronic
|
0.400 |
Biomarker
|
disease |
BEFREE |
Intravenous Epoetin Alfa-epbx versus Epoetin Alfa for Treatment of Anemia in End-Stage Kidney Disease.
|
29921734 |
2018 |
|
Kidney Failure, Chronic
|
0.400 |
Biomarker
|
disease |
BEFREE |
Darbepoetin alfa (DA); hyper-glycosylated Erythropoietin alfa (EPO) is an essential treatment of anemia in patients with chronic kidney failure and cancer.
|
29157782 |
2018 |
|
Kidney Failure, Chronic
|
0.400 |
Biomarker
|
disease |
BEFREE |
Recombinant human erythropoietin, such as epoetin alfa and darbepoetin alfa, is an important therapy for anemia due to chronic renal failure.
|
29545827 |
2018 |
|
Kidney Failure, Chronic
|
0.400 |
Biomarker
|
disease |
BEFREE |
Anaemia is a very common problem in patients with end-stage kidney disease (ESKD) and the use of erythropoietin-stimulating agents (ESA) has revolutionised its treatment.
|
29178879 |
2017 |
|
Kidney Failure, Chronic
|
0.400 |
Biomarker
|
disease |
BEFREE |
In summary, we provided evidence addressing the potential correlation between the immune repertoire and EPO response in ESRD patients.
|
28697735 |
2017 |
|
Kidney Failure, Chronic
|
0.400 |
Biomarker
|
disease |
BEFREE |
Attempts to fully reverse anemia in ESRD with excessive stimulation of erythropoiesis enhances the number of circulating suicidal erythrocytes and bears the risk of interference with micocirculation, At least in theory, anemia in ESRD could preferably be treated with replacement of erythropoietin and additional inhibition of eryptosis thus avoiding eryptosis-induced impairment of microcirculation.
|
29151105 |
2017 |
|
Kidney Failure, Chronic
|
0.400 |
Biomarker
|
disease |
BEFREE |
A Comparison of the Safety and Efficacy of HX575 (Epoetin Alfa Proposed Biosimilar) with Epoetin Alfa in Patients with End-Stage Renal Disease.
|
29084409 |
2017 |
|
Kidney Failure, Chronic
|
0.400 |
Biomarker
|
disease |
BEFREE |
These agents work by stabilizing the HIF complex and stimulating endogenous erythropoietin production even in patients with end-stage kidney disease.
|
28242135 |
2017 |
|
Kidney Failure, Chronic
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The vascular endothelial growth factor (VEGF) has been implicated as a major contributor to CRD disease progression, thus our aim was to profile the VEGF levels in patients with ESRD and to determine the effects of the erythropoietin stimulating agents (ESAs).
|
27081865 |
2017 |
|
Kidney Failure, Chronic
|
0.400 |
Biomarker
|
disease |
BEFREE |
Recombinant human EPO is currently used clinically for the treatment of anemia in patients with end-stage renal disease, and in certain cancer patients suffering from anemia induced either by the tumor itself or by chemotherapy.
|
28871174 |
2017 |
|
Kidney Failure, Chronic
|
0.400 |
Biomarker
|
disease |
BEFREE |
Management of CKD focuses primarily on replacing renal functions such as erythropoietin, 1,25-hydroxylation of vitamin D, electrolyte homeostasis/excretion, and, in ESRD, waste product removal.
|
27733241 |
2017 |
|
Kidney Failure, Chronic
|
0.400 |
Biomarker
|
disease |
BEFREE |
Since the 1990s, EPO has been used for the treatment of anemia associated with end-stage renal failure and chemotherapy.
|
28104107 |
2017 |
|
Kidney Failure, Chronic
|
0.400 |
Biomarker
|
disease |
BEFREE |
Recombinant human erythropoietin is an important therapeutic protein with high economic interest due to the benefits provided by its clinical use for the treatment of anemias associated with chronic renal failure and chemotherapy.
|
28988419 |
2017 |
|
Kidney Failure, Chronic
|
0.400 |
Biomarker
|
disease |
BEFREE |
EPO has been widely used in the treatment of chronic renal failure, cancer, and chemotherapy-related anemia for three decades.
|
28629521 |
2017 |
|
Kidney Failure, Chronic
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We found little evidence for the association of the EPO promoter polymorphism, rs161740, with the combined phenotype of proliferative retinopathy and end-stage renal disease in U.K.-R.O.I.
|
22721967 |
2012 |
|
Kidney Failure, Chronic
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Recently, it was demonstrated that the T allele of SNP rs1617640 in the promoter of the erythropoetin (EPO) gene is significantly associated with proliferative diabetic retinopathy (PDR) and end-stage renal disease (ESRD) due to increased EPO expression.
|
21092038 |
2010 |
|
Kidney Failure, Chronic
|
0.400 |
Biomarker
|
disease |
BEFREE |
Erythropoietin regulates intestinal iron absorption in a rat model of chronic renal failure.
|
20631677 |
2010 |
|
Kidney Failure, Chronic
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Compared with controls, circulating VE-cadherin, CD146, Flk1, VEGF, and EPO RNA levels were decreased in ESRD and normalized in transplanted patients.
|
18852688 |
2009 |
|
Kidney Failure, Chronic
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
These results suggest that rs1617640 in the EPO promoter is significantly associated with PDR and ESRD.
|
18458324 |
2008 |
|
Kidney Failure, Chronic
|
0.400 |
Biomarker
|
disease |
BEFREE |
Recombinant human erythropoietin (EPO), which is routinely used to treat the anaemia present in approximately 90% of dialysis-dependent patients with end-stage renal disease, may induce vascular dysfunction by reducing nitric oxide (NO) availability.
|
18204093 |
2008 |